US Food and Drug Administration (FDA)

The new generic formulation matches the composition of Celgene’s original Pomalyst medication and comes in four different strengths: 1mg, 2mg, 3mg, and 4mg.

The U.S. Food and Drug Administration (FDA) recently approves an updated label for UNLOXCYT based on long-term follow-up data from the pivotal CK-301-101 clinical trial.

The therapy is indicated for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype.

The Bendit17 microcatheter incorporates Bendit’s proprietary real-time 3D steering technology, which enables clinicians to maneuver the device more intuitively through complex vascular pathways.

Waskyra is specifically indicated for pediatric patients aged six months and older, as well as adults diagnosed with WAS who have a mutation in the WAS gene.

The newly approved toolbox serves as a sophisticated aid for healthcare professionals who need to identify signs of acute deterioration in their inpatient populations.

The test distinguishes between three distinct Bordetella species that cause different types of illness: B. pertussis, B. parapertussis and B. holmesii

The FDA’s latest decision also extends the audiologic and speech indications to children aged 12 months and older, broadening the potential patient population who can benefit from this technology.

Macaque monkeys serve as the most common species for drug testing because they share considerable physiological similarities with humans.

The therapy delivers the full-length human frataxin gene using a dual-administration approach that combines direct intradentate nucleus (IDN) injection with intravenous (IV) infusion.